Epithelial Biology Center Archives
Colon cancer researchers awarded NCI grant for study of early lesions
Sep. 22, 2022—Vanderbilt researchers are studying precancerous lesions and early cancers in the colon, with the goal of developing new ways to prevent colorectal cancer, the nation’s second leading cancer killer.
Probing the tumor microenvironment
Jul. 12, 2022—Vanderbilt researchers used single-cell sequencing, imaging, and computational approaches to characterize the colonic tumor microenvironment, providing important insights to the components that play roles in colorectal tumor pathogenesis.
Molecular ‘switch’ may illuminate stomach disorders
May. 19, 2022—An international team that included researchers from Vanderbilt University Medical Center has discovered a molecular switch that induces rapid proliferation of zymogen granule-secreting chief cells in the stomach to regenerate damaged tissue.
The role of polarity in early cancer
Sep. 21, 2021—Mutations in the protein epiregulin, an EGF receptor ligand, affect larger epithelial cell reorganization and may contribute to early cancer development, Vanderbilt researchers discovered.
Vega selected as 2021 Vanderbilt Prize Student Scholar
Aug. 11, 2021—Paige Vega, a PhD student in the Department of Cell and Developmental Biology at Vanderbilt University, has been selected as the 2021 Vanderbilt Prize Student Scholar.
Studying cells in reduced dimensions
Jun. 18, 2020—Vanderbilt cell biologists have developed an unbiased, quantitative framework for evaluating single-cell data.
Cancer Moonshot award to help map tumor progression
Sep. 27, 2018—A trans-institutional team of researchers at Vanderbilt University Medical Center and Vanderbilt University has received an $11 million Cancer Moonshot grant to build a single-cell resolution atlas to map out the routes that benign colonic polyps take to progress to colorectal cancer, the third most common cancer among both men and women in the United States.
Researchers find novel mechanism of resistance to anti-cancer drugs
Oct. 17, 2017—Vanderbilt investigators have discovered a novel non-genetic cause of resistance to the targeted anti-cancer therapy cetuximab. Their findings, reported this week in Nature Medicine, suggest a strategy for overcoming this resistance.
Coffey lands major NCI award to support colorectal cancer research
Jun. 8, 2017—Vanderbilt’s Robert Coffey Jr., M.D., has received an Outstanding Investigator Award from the National Cancer Institute (NCI) — more than $6.6 million over seven years — to support studies aimed at advancing the diagnosis and treatment of colorectal cancer (CRC), a leading cancer killer.
Glowing receptors help find and track cancerous growth
May. 18, 2017—Under the microscope, they sparkle like emeralds, these molecules that may hold a key to understanding — and stopping — cancerous growth.
Study seeks to reverse precancerous stomach lesions
May. 4, 2017—Vanderbilt University Medical Center cancer researcher James Goldenring, M.D., Ph.D., has received a two-year, $200,000 grant from the DeGregorio Family Foundation in Pleasantville, New York, to begin clinical trials of a potential approach for reversing precancerous stomach lesions.
Study takes 3-D perspective on colorectal cancer
Mar. 23, 2017—Despite dramatic recent advances in treatment, colorectal cancer killed more than 49,000 Americans last year, according to the National Cancer Institute, making it the second most lethal malignancy after cancers of the lung and bronchus.
